Posts by Ryan Corcoran, MD, PhD
-
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
-
Liquid Biopsy Outperforms Standard Biopsy for Characterizing Acquired Resistance in Gastrointestinal Cancers
In patients whose cancer progressed on targeted therapy, analysis of circulating tumor DNA in a blood sample ("liquid biopsy") was superior to tissue biopsy for identifying heterogeneous resistance alterations critical to the selection of subsequent therapy, according to research at the Mass General Cancer Center.
Biography
Dr. Corcoran is assistant professor in the Cancer Center at Massachusetts General Hosipital. His work focuses on targeted therapies directed against specific mutations commonly found in human cancers, with a focus on BRAF and KRAS mutant gastrointestinal cancers.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
